Various targeted therapies have demonstrated single‐agent activity in relapsed/refractory (R/R) DLBCL, including the immunomodulatory drug (iMiD) agent lenalidomide [11, 12], the Bruton tyrosine kinase (BTK) inhibitor ibrutinib [13], and the mammalian target of rapamycin (mTOR) inhibitor temsirolimus [14]. This evidence concerns the gene BTK and diffuse large B-cell lymphoma.